Skip to main content
SpringerLink
Log in

Role of Metabolic Imaging in Mesothelioma

  • Chapter
  • First Online:
Mesothelioma

Abstract

Early diagnosis and clinical staging in patients affected by malignant pleural mesothelioma (MPM) is necessary to manage individual therapy strategies. Computed tomography (CT) and magnetic resonance imaging (MRI) are routinely used for non-invasive clinical staging. Because of the complex growth pattern of MPM, it is difficult to make a clinical judgement only with morphological imaging, so 18F-FDG PET-CT represent an important adjunctive imaging tool in these patients. 18F-FDG PET-CT can be useful in detecting malignant pleural mesothelioma in patients exposed to asbestos and distinguish asbestos-related benign lesions. Combined PET-CT is essential for selecting patients with resectable disease, increasing the detection of locally advanced tumour and improve the accuracy of preoperative staging. 18F-FDG PET-CT could be useful also in risk stratification, to avoid radical surgery in cases characterized by the worst prognosis. PET-CT is gradually becoming essential in assessment of tumour response in patients undergoing chemotherapy. Metabolic imaging analysis permits the early identification of non-responders to chemotherapy, avoiding unsuccessful treatment, characterized by important toxicities and high mortality risk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Benamore RE, et al. Use of imaging in the management of malignant pleural mesothelioma. Clin Radiol. 2005;60:1237–47.

    Article  CAS  Google Scholar 

  2. Wang ZJ, et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004;24:105–19.

    Article  Google Scholar 

  3. Blodgett TM, et al. PET/CT: form and function. Radiology. 2007;242(2):360–85.

    Article  Google Scholar 

  4. Pinilla I, et al. Integrated 18FDG PET/CT: utility and applications in clinical oncology. Clin Med Oncol. 2008;2:181–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Boellaard R, et al. FDG PET/CT: EANM procedure guidelines for tumor imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.

    Article  CAS  Google Scholar 

  6. Kinahan PE, et al. PET/CT standardized uptake values (SUVs) in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010;31:496–505.

    Article  Google Scholar 

  7. Yildirim H, et al. Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol. 2009;4(12):1480–4.

    Article  Google Scholar 

  8. Terada T, et al. Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma. Exp Ther Med. 2012;4:197–200.

    Article  Google Scholar 

  9. Sun Y, et al. The role of 18F-FDG PET/CT integrated imaging in distinguishing malignant from benign pleural effusion. PLoS One. 2016;11(8):e0161764.

    Article  Google Scholar 

  10. Asad S, et al. False-positive FDG positron emission tomography uptake in nonmalignant chest abnormalities. Am J Roentgenol. 2004;182:983–9.

    Article  Google Scholar 

  11. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the international mesothelioma interest group. Chest. 1995;108(4):1122–8.

    Article  CAS  Google Scholar 

  12. Patz EF Jr, et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. Am J Roentgenol. 1992;159:961–6.

    Article  Google Scholar 

  13. Flores RM, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126(1):11–6.

    Article  Google Scholar 

  14. Frauenfelder T, et al. Use of computed tomography and positron emission tomography/computed tomography for staging of local extent in patients with malignant pleural mesothelioma. J Comput Assist Tomogr. 2014;39(2):160–5.

    Article  Google Scholar 

  15. Erasmus JJ, et al. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg. 2005;129(6):1364–70.

    Article  Google Scholar 

  16. Sørensen JB, et al. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2008;34:1090–6.

    Article  Google Scholar 

  17. Schneider DB, et al. Positron emission tomography with F18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2000;120(1):128–33.

    Article  CAS  Google Scholar 

  18. Lee ST, et al. Prognostic value of 18F-FDG PET/CT in patients with malignant pleural mesothelioma. Mol Imaging Biol. 2009;11:473–9.

    Article  CAS  Google Scholar 

  19. Kitajima K, et al. Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. Eur J Radiol. 2017;86:176–83.

    Article  Google Scholar 

  20. Lee HY, et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2017;17:2787–94.

    Article  Google Scholar 

  21. Byrne MJ, et al. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15:257–60.

    Article  CAS  Google Scholar 

  22. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983–95.

    CAS  PubMed  Google Scholar 

  23. Ceresoli GL, et al. Assessment of tumour response in malignant pleural mesothelioma. Cancer Treat Rev. 2007;33(6):533–41.

    Article  Google Scholar 

  24. Kanemura S, et al. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. Eur J Radiol. 2017;86:92–8.

    Article  Google Scholar 

  25. Lopci E, et al. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging. 2015;42:667–75.

    Article  Google Scholar 

  26. Zucali PA, et al. Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. Cancer Med. 2017;6(10):2287–96.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biomedical Sciences, Humanitas University, Milan, Italy

    Fabrizia Gelardi & Arturo Chiti

  2. Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy

    Andrea Marciano & Paola Anna Erba

  3. Nuclear Medicine, Humanitas Research Hospital, Milan, Italy

    Arturo Chiti

Authors
  1. Fabrizia Gelardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Marciano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Anna Erba
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arturo Chiti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arturo Chiti .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Giovanni Luca Ceresoli

  2. Scientific Direction, Humanitas Gavazzeni Hospital, Bergamo, Italy

    Emilio Bombardieri

  3. Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy

    Maurizio D'Incalci

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gelardi, F., Marciano, A., Erba, P.A., Chiti, A. (2019). Role of Metabolic Imaging in Mesothelioma. In: Ceresoli, G., Bombardieri, E., D'Incalci, M. (eds) Mesothelioma. Springer, Cham. https://doi.org/10.1007/978-3-030-16884-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16884-1_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16883-4

  • Online ISBN: 978-3-030-16884-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation